Lv1
20 积分 2024-09-01 加入
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
16小时前
待确认
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
16小时前
已完结
Pro- and anti-inflammatory roles of interleukin (IL)-33, IL-36, and IL-38 in inflammatory bowel disease
17天前
已完结
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials
18天前
已完结
Expression, Solubilization, Refolding and Final Purification of Recombinant Proteins as Expressed in the form of “Classical Inclusion Bodies” in E. coli
23天前
已完结
Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors
1个月前
已完结
Pathophysiology, diagnosis, and management of endometriosis
1个月前
已完结
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
1个月前
已完结
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
1个月前
已完结
The IL-33 and IL-4Rα blocking antibodies itepekimab and dupilumab modulate both distinct and common inflammatory mediators in asthma
1个月前
已完结
皖公网安备34019202002308
